Thomas Trimarchi Sells 16,934 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Thomas Trimarchi sold 16,934 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $66.46, for a total transaction of $1,125,433.64. Following the completion of the transaction, the chief financial officer directly owned 382,830 shares in the company, valued at approximately $25,442,881.80. This represents a 4.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Thomas Trimarchi also recently made the following trade(s):

• On Thursday, August 21st, Thomas Trimarchi sold 42,237 shares of BridgeBio Pharma stock. The stock was sold at an average price of $49.48, for a total transaction of $2,089,886.76.

BridgeBio Pharma Trading Down 0.1%

NASDAQ BBIO opened at $65.54 on Thursday. The firm’s 50 day simple moving average is $57.23 and its 200 day simple moving average is $48.21. The firm has a market capitalization of $12.63 billion, a price-to-earnings ratio of -15.68 and a beta of 1.39. BridgeBio Pharma, Inc. has a 1 year low of $22.05 and a 1 year high of $69.48.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Wednesday, October 29th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). The business had revenue of $120.70 million during the quarter, compared to analysts’ expectations of $107.71 million. BridgeBio Pharma’s revenue was up 4318.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.86) EPS. On average, equities research analysts forecast that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Analysts Set New Price Targets

BBIO has been the subject of several recent analyst reports. Evercore ISI restated an “outperform” rating on shares of BridgeBio Pharma in a research report on Monday, October 27th. Wall Street Zen raised BridgeBio Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Cowen reissued a “positive” rating on shares of BridgeBio Pharma in a report on Thursday, October 30th. Cantor Fitzgerald lifted their price target on shares of BridgeBio Pharma from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $90.00 price objective on shares of BridgeBio Pharma in a research report on Monday, November 3rd. Twenty equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BridgeBio Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $74.37.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Moss Adams Wealth Advisors LLC lifted its position in shares of BridgeBio Pharma by 49.2% during the 2nd quarter. Moss Adams Wealth Advisors LLC now owns 24,172 shares of the company’s stock valued at $1,044,000 after acquiring an additional 7,970 shares during the period. Baird Financial Group Inc. acquired a new stake in BridgeBio Pharma in the first quarter worth $1,429,000. Victory Capital Management Inc. increased its stake in BridgeBio Pharma by 22.8% in the first quarter. Victory Capital Management Inc. now owns 79,851 shares of the company’s stock valued at $2,760,000 after purchasing an additional 14,825 shares in the last quarter. Intech Investment Management LLC raised its holdings in shares of BridgeBio Pharma by 12.0% during the first quarter. Intech Investment Management LLC now owns 73,524 shares of the company’s stock valued at $2,542,000 after purchasing an additional 7,877 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of BridgeBio Pharma by 15.3% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,335 shares of the company’s stock worth $317,000 after purchasing an additional 971 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.